

Delivering precision antimicrobial therapy through closed-loop control systems

T. M. Rawson^{1*}, D. O'Hare², P. Herrero³, S. Sharma⁴, L. S. P. Moore^{1,5}, E. de Barra⁵, J. A. Roberts^{6,7}, A. C. Gordon⁸, W. Hope⁹, P. Georgiou³, A. E. G. Cass¹⁰ and A. H. Holmes^{1,5}

¹National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK; ²Department of Bioengineering, Imperial College London, London SW7 2AZ, UK; ³Department of Electrical and Electronic Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, UK; ⁴College of Engineering, Swansea University, Swansea SA1 8EN, UK; ⁵Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, Acton W12 0NN, UK; ⁶University of Queensland Centre for Clinical Research, Faculty of Medicine and Centre for Translational Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, Australia; ⁷Royal Brisbane and Women's Hospital, Brisbane, Australia; ⁸Section of Anaesthetics, Pain Medicine & Intensive Care, Imperial College London, London SW7 2AZ, UK; ⁹Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GE, UK; ¹⁰Department of Chemistry & Institute of Biomedical Engineering, Imperial College London, Kensington Campus, London SW7 2AZ, UK

*Corresponding author. Health Protection Research Unit in Healthcare Associated Infections & Antimicrobial Resistance, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. Tel: 44-20-3313-2732; E-mail: timothy.rawson07@imperial.ac.uk

Sub-optimal exposure to antimicrobial therapy is associated with poor patient outcomes and the development of antimicrobial resistance. Mechanisms for optimizing the concentration of a drug within the individual patient are under development. However, several barriers remain in realizing true individualization of therapy. These include problems with plasma drug sampling, availability of appropriate assays, and current mechanisms for dose adjustment. Biosensor technology offers a means of providing real-time monitoring of antimicrobials in a minimally invasive fashion. We report the potential for using microneedle biosensor technology as part of closed-loop control systems for the optimization of antimicrobial therapy in individual patients.

Introduction

Antimicrobial resistance (AMR) threatens to be a leading cause of death by 2050¹ making it a global patient safety issue. A major driver of AMR is the inappropriate use of antimicrobials in humans and animals.² To date, research in this field has focused on optimizing the selection of antimicrobial agents. However, these strategies often fail to also consider optimization of the dose of the antimicrobial agent, which should aim to be sufficient to maximize bacterial killing whilst negating the harmful consequences of therapy, such as development of AMR and toxicity to the host.

Data are emerging within certain patient populations, such as critically ill patients, describing wide variations in how individuals handle antimicrobials (pharmacokinetics; PK).^{3–7} These wide variations in individual PK appear to be associated with increased variation in the effects of therapy, including outcomes of treatment and the development of AMR (their pharmacodynamics; PD).^{3–7} In response to the observed variations in individual PK, there has been a shift in the focus of therapeutic drug monitoring (TDM) away from primarily being used to prevent toxicity caused by antimicrobials with narrow therapeutic windows, towards enhancing the efficacy of less toxic agents such as the β -lactams, in order to

optimize the outcomes of treatment.^{4,8–13} However, to achieve true individualization of therapy, we require a focus on not just the PK of antimicrobial agents. We must also understand the individual patient's physiology as well as the characteristics of the organism that we are treating. One method that has been explored widely is the use of Bayesian dose optimization platforms.³ Whilst TDM linked with Bayesian forecasting provides a powerful opportunity for delivering individualized care for patients,^{3,14} several gaps in current strategies for dose optimization of antimicrobials have hindered clinical implementation. Most notably, methods for more-continuous monitoring to allow real-time adaptive dosing of agents are still not available. Other challenges include difficulties in access to appropriate antimicrobial assays,^{12,15–20} poor integration of dosing software with electronic health records and decision support systems,^{3,21} challenges with collecting and handling PK samples,^{22,23} and failures of compliance with PK sampling protocols currently being used by healthcare professionals.²⁴

Validation of novel methods for the monitoring and dose optimization of antimicrobial agents is required. Whilst several studies have explored the role of microfluidics,^{22,23,25} these are still hindered by many of the problems associated with routine antimicrobial TDM strategies, such as the need for laboratory analysis and




Figure 1. Schematic for closed-loop control of antimicrobial delivery.

transport of blood products. One potential method for avoiding these problems is the development of closed-loop systems based on minimally invasive, microneedle electrochemical sensor technology.²⁶ This technology has been demonstrated to be applicable to the management of other conditions, such as diabetes control through individualized insulin delivery^{27–31} and anaesthesia control intra-operatively.^{32,33} This approach offers a potential avenue for enhancing the precision of antimicrobial therapy across a number of settings where invasive monitoring techniques may not be appropriate, including the community and non-critical care hospital settings. We report the current state of the art within the field of infection that offers a novel approach for the development of closed-loop systems for precision antimicrobial dosing.

Concept of closed-loop control for individualized antimicrobial therapy

There are several key concepts outlined in Figure 1 that must be considered for the development of closed-loop controllers for antimicrobial therapy. Ideally, monitoring of antimicrobials should be continuous and in a minimally invasive format that does not rely on blood sampling. The development of microneedle array biosensor technology has provided an opportunity to achieve this, allowing for detection of antimicrobial concentrations in the dermal interstitial fluid (ISF).^{34,35} This technology has already been validated in the field of diabetes,

demonstrating safety and tolerability in human clinical trials and accuracy in diabetic individuals who tend to have poor tissue perfusion due to underlying diabetic vasculopathy.^{26,34,35} Given that the free antimicrobial concentration in the ISF is generally in equilibrium with the plasma concentration this provides an opportunity for using this technology to monitor ISF concentrations as well as estimate plasma antimicrobial concentration in near real-time without requiring plasma sampling.^{36–38} This may be challenging in certain situations, such as during periods of tissue hypoperfusion in critically ill patients in the intensive care unit (ICU).³⁹ However, it may also offer a novel option for supporting the optimization of antimicrobial dosing in these populations. This is because the majority of infections occur in tissue ISF.^{39,40} Therefore, this technology may provide a mechanism for monitoring antimicrobial concentrations in a compartment that is closer to the site where the infection is being treated when compared with plasma.^{39,40}

Data generated by this sensor can then be linked with machine-driven, closed-loop control algorithms such as Proportional-Integral-Derivative (PID)⁴¹ and Iterative Learning Controllers (ILC).⁴² These systems will allow for the optimization of both continuous and bolus (or oral) therapy to drive individualized target attainment of pre-defined PK/PD indices associated with maximal bacterial killing and/or suppression of the emergence of AMR.^{43,44} These may be current gold standard PK/PD targets^{45,46} or novel indices, such as AUC:EC₅₀ ratio.^{47,48}

Each of these concepts will individually be explored and critiqued within this manuscript.

Microneedles for continuous sensing of agents in the dermal interstitial fluid

Microneedle technology was first demonstrated as a suitable mechanism for drug monitoring and delivery over 20 years ago.⁴⁹ Since then, microneedle technology has progressed rapidly with data supporting the use of microneedles to monitor glucose and lactate concentrations in humans^{34,35,50,51} as well as acting as delivery systems for drugs and vaccines.^{30,52} Microneedles work by penetrating the stratum corneum layer of the skin allowing access to the ISF, whilst avoiding the nerve fibres and blood vessels that are found within the dermis. Therefore, this offers a minimally invasive method for drug or metabolite monitoring.^{34,35,50,51} Side effects such as pain, bleeding, skin reactions, and infection risk have all previously been explored and shown to be minimal following application of such devices to the skin.³⁴

One example of such technology was recently reported by Sharma and colleagues,²⁸ who demonstrated high reproducibility when using microneedle technology to monitor glucose levels in healthy volunteers compared with capillary blood glucose measurements. The authors were able to demonstrate robustness of the device to sterilization using gamma-irradiation thus allowing the device to be sterilized and stored over time for use in monitoring human glucose concentrations.²⁸ Furthermore, this technology can be reproduced reliably and at low cost through the development of scalable microneedle fabrication batch processing, producing up to 300 microneedles every hour.⁵⁰

However, there are also challenges that remain in the development of microneedles within this field. Whilst microneedle-based methods of microdialysis have also been reported for the monitoring of vancomycin,⁵³ this technique requires transfer of small volumes of ISF, which not only presents technical challenges in maintaining accuracy of the sensor but also leads to delays that mitigate against their application in real-time control.⁵³ Moreover, in clinical trials for monitoring glucose using glucose oxidase-coated microneedles, the sensors appear to occasionally generate artefact during movements that cause them to be partially removed from the intradermal space.²⁸ Whilst the artefact present in previous human studies had a shorter duration than changes in glucose concentration, this still requires consideration. Another challenge encountered with current microneedle sensors in humans has been accuracy of these devices at extreme ranges of glucose, especially hypoglycaemic ranges.²⁸ It is likely therefore that sensor deployment for antimicrobial monitoring will encounter similar barriers for consideration.

In addition to microneedle-based sensing, other methods to facilitate continuous monitoring are also under consideration. Probably the most developed are attempts to perform real-time monitoring of drug concentrations in ambulatory animals using invasive vascular catheter insertion.⁵⁴ These would only be acceptable in very specific situations in clinical practice, such as critical care or at the time of surgery, where tissue hypoperfusion may influence the ability of microneedle devices to accurately predict free drug concentrations in blood. However, invasive devices pose

their own risks to the patient, including thrombosis.⁵⁴ This type of invasive device would not be acceptable in the vast majority of individuals who receive antimicrobial therapy outside of critical care in hospital or in the community settings. A second consideration is the use of non-invasive, sweat-based monitoring systems as have been developed for glucose monitoring. However, to date very few data exist on whether this would be a viable option for monitoring antimicrobial concentrations.⁵⁵

Antimicrobial electrochemical sensing

Electrochemical sensors for antimicrobials in the environment, agriculture, and humans have been demonstrated for a wide range of agents used in human medicine (Table 1). In the literature, electrochemical sensors for the detection and monitoring of antimicrobials are largely based on aptamer, antibody-linked, or enzyme-based sensors.^{54,56,57} These have demonstrated high sensitivity for monitoring of antimicrobials in potentially physiological ranges seen in ISF.²⁶ However, there remains a paucity of data for many antimicrobial agents to accurately support the ability of these devices to predict the PK in both tissue and plasma at present. Aptamer sensors are nucleic acid-based and are highly specific for their target molecule, producing their signal through the detection of a redox reaction on ligand binding. Engineered using an *in vitro* selection procedure, called Systematic Evolution of Ligands by EXponential enrichment (SELEX) they have been reported to have a high sensitivity down to the range of picomoles in monitoring of certain environmental contaminants.⁵⁶ One such aptamer-based sensor is the MEDIC device, described by Ferguson and colleagues.⁵⁴ This device has been demonstrated in live animal models to be able to monitor in real time a number of different agents, including kanamycin, using a liquid phase filter to prevent interference from blood-fouling of the DNA aptameric sensor.⁵⁴ Within that study, live rats were injected with increasing doses of kanamycin, an aminoglycoside antibiotic, at hourly intervals to demonstrate the ability to monitor the PK profile in real time using an aptamer sensor in the bloodstream.⁵⁴ Aminoglycoside aptamers have also been tested against spiked human serum demonstrating accuracy for determining concentrations of routine, clinically observed targets between 2 and 6 μM .

Enzymatic penicillin G sensors are some of the oldest antimicrobial sensors reported in the literature.⁵⁷ These reactions can be detected through electrical, optical, or calorimetric methods.⁵⁸ The majority of these techniques detect the hydrolysis of penicillin to penicillinoic acid and a hydrogen ion. One recent example of this technology is reported by Ro-Lee and colleagues utilizing field effect devices.⁵⁹ The authors describe the high sensitivity of the enzyme-based device, its stability during storage, and re-usability over a 30 day period.⁵⁹

These mechanisms for antimicrobial sensing have so far been demonstrated on microchips, disc electrodes, and nanotubes. This makes the devices small and highly transportable. This technology must now be transferred and tested on microneedle array devices to explore the sensitivity of such systems for real-time antimicrobial monitoring. However, based on current evidence provided by microdialysis of critically ill patients'

Table 1. Current antimicrobial sensor classes reported in the literature

Sensor	Setting demonstrated	Ranges of detection in study	Ref
Macrolides	<ul style="list-style-type: none"> Spiked human urine Water samples Optimal analytical conditions 	<i>In spiked human urine:</i> 0–2 µM (azithromycin)	83,84
Quinolones	<ul style="list-style-type: none"> Spiked human plasma Spiked human urine Milk Optimal analytical conditions 	<i>In spiked human plasma:</i> 0.05–100 µM (CIP) 0.1–100 µM (OFX) 0.1–40 µM (NOR) 0.06–100 µM (GAT)	85–90
Chloramphenicol	<ul style="list-style-type: none"> Milk Spiked human urine Food samples Optimal analytical conditions 	<i>In food samples:</i> 0.08–1392 µM LLD 0.015 µM	91–94
Metronidazole	<ul style="list-style-type: none"> Spiked human urine Optimal analytical conditions 	<i>Calibration in lab:</i> Linear range 0.8 pM–720 nM <i>In spiked urine samples reported recovery at concentrations</i> 87, 96, 110, and 123 µM	95
Tetracyclines	<ul style="list-style-type: none"> Meat/feedstuff samples Spiked honey Optimal analytical conditions 	<i>In feedstuff</i> Linear range 0.3–52.0 µM (tetra) LLD 0.10 µM (tetra)	96,97
Rifampicin	<ul style="list-style-type: none"> Optimal analytical conditions 	<i>Linear detection ranges:</i> 0.006–10.0 mmol/L with an LLD of 4.16 nmol/L and 0.04–10 mmol/L with an LLD of 2.34 nmol/L	98
Penicillins	<ul style="list-style-type: none"> Optimal analytical conditions Food/milk samples 	<i>In spiked milk samples:</i> linear range 3–283 µM and LLD 0.3 µM (Pen-G) Recovery from spiked samples was 102 ± 6% <i>In optimal conditions:</i> Km value 67 ± 13 µM reported using Michaelis Menten kinetics equation (Pen-G)	26,58,59, 99–113
Aminoglycosides	<ul style="list-style-type: none"> Optimal analytical conditions Ambulatory animals bloodstream Spiked human serum 	<i>In spiked human serum:</i> Accurate within therapeutic range of 2–6 µM	52,98, 114–118
Lincomycin	<ul style="list-style-type: none"> Optimal analytical conditions Foodstuff Spiked human urine 	<i>In optimal conditions:</i> Linear detection range up to 1 mM and LLD of 0.08 µM <i>In spiked human urine:</i> Recovery in samples was 96.44% to 103.26%	119
Sulphonamides	<ul style="list-style-type: none"> Optimal analytical conditions Milk Spiked human urine 	<i>In optimal conditions:</i> Range of 0.1–10.0 mmol/L with LLD of 60 nmol/L (TMP) AND 1.0–10.0 mmol/L with LLD of 38 nmol/L (SMX) <i>In spiked urine:</i> Recovery 91.3%–101%	120–122

CIP, ciprofloxacin; OFX, ofloxacin; GAT, gatifloxacin; NOR, norfloxacin; TMP, trimethoprim; SMX, sulfamethoxazole; Pen-G, penicillin G; LLD, lower limit of detection.

tissue ISF concentrations, this approach is a potential avenue for estimation of antimicrobial concentrations and real-time monitoring.^{36–38} Preliminary *in vitro* work exploring the monitoring of β-lactam antibiotics (penicillin G, amoxicillin, and

ceftriaxone) in artificial ISF using microneedles has demonstrated such devices provide plausible results.²⁶ However, the major gap in the literature supporting translation currently is a paucity of human, *in vivo* studies with such biosensors to

demonstrate their resistance to biofouling from proteins such as albumin and immunoglobulins.^{60,61} Furthermore, there remains limited data on the expected free antibiotic concentrations within the ISF for many antibiotics to predict the characteristics of tissue PK and allow accurate estimates of the linear range of response that such sensors will be required to work in before translation into human studies.

Closed-loop control for drug delivery

Closed-loop controllers have a broad application in the field of diabetes, being the cornerstone of novel developments, such as the artificial pancreas system.^{31,62} Furthermore, closed-loop control has been demonstrated as effective in controlling delivery of both intravenous and inhaled anaesthetic agents during surgery.^{32,63} This technology has been demonstrated in pre-clinical and *in silico* studies to be transferable to optimization of antimicrobial dosing.^{54,63} Two of the most widely used controllers for continuous and intermittent bolus infusions are the PID and ILC controllers, respectively.^{43,44} These controllers are algorithms that optimize the delivery of an agent against a pre-determined set point.

PID control

PID controllers depend on constant monitoring (e.g. every 5 minutes) and can be used to control continuous infusions maintaining drug concentrations at a set target (e.g. either target concentration or PK/PD index). As their name suggests, following data input the PID has three coefficients; the proportional, integral, and derivative. It alters these three coefficients to optimize the response against its target for therapy. The simplicity and robustness of PID algorithms make them extremely suitable for the range of operating conditions found in healthcare. This may be especially useful in critical care, where there is currently a drive towards continuous infusions of β -lactam antimicrobials and nephrotoxic agents, such as vancomycin, to optimize the PK exposure and PD properties.^{38,64–70} However, where current protocols require sporadic plasma TDM sampling this mechanism offers an opportunity for real-time response to changes in individual patient PK. For example, this would account for variations in PK caused by changes in the patient's inflammatory response, fluid shifts, augmented renal clearance, and in changing drain outputs in surgical patients that may currently be missed with sporadic TDM sampling.^{71–74}

ILC in closed-loop control

ILC provides the option for optimization of bolus or oral therapy, with data from continuous monitoring being used to optimize the amount, timing, and rate at which a bolus (or oral dose) is delivered. Like PID, ILC algorithms have wide applications but work on the assumption that during repetitive tasks (such as antimicrobial bolus dosing at regular intervals) there will be some level of error in target attainment (e.g. overshoot or undershoot). Therefore, the ILC aims to adjust the input, in this case the bolus dose, to reduce the transient error encountered during routine drug delivery to optimize the accuracy of such systems. This may be more applicable to non-critical care or the community setting (such as outpatient parenteral therapy or oral dosing) and in specialist

populations, such as paediatrics and pregnancy, where rich data collection will allow for tailored therapy to be determined and adjusted for, based on real-time data and potentially previous experience housed within machine learning algorithms, as has been demonstrated by the use of Case-Based Reasoning in diabetes management.⁷⁵

These systems can automatically control the delivery of an agent to optimize drug delivery to achieve defined PK/PD targets. If linked with Bayesian dose optimization software or Case-Based Reasoning platforms, which can provide individualized initial dose selection, and novel *in vivo* mechanisms of predicting antimicrobial PD, these could offer a powerful mechanism for reducing the errors that are commonly observed in the practice of current dose optimization strategies.

In terms of translating these into microneedle sensor-driven closed-loop control systems, the biggest challenge remaining is accurately describing the relationship for individual antimicrobials between tissue and plasma PK, especially during the initial phase of dosing, when the drug is not at steady state. This will be required to accurately describe the relationship between free concentrations of drug in both compartments and will likely require rich plasma and microdialysis PK sampling to enable development of accurate algorithms to support such controllers.

Additional PK/PD indices for individualizing therapy

Currently, individualized PK/PD indices rely on factors such as the MIC to form part of time- and concentration-dependent measures for exposure response (such as AUC:MIC, Time>MIC, or Peak:MIC). MIC as a PD target requires isolation of the causative pathogen and determination of the individual organism's susceptibility. This causes a practical problem in cases where the invading pathogen is not identified, as is observed during the empirical phase of antimicrobial therapy, and in a significant proportion of cases of sepsis that remain culture-negative throughout the treatment period.^{76,77} Therefore, in the absence of microbiology results, population-level assumptions are made about the most likely organism causing the infection and the average MIC of this population. Thus this does not provide a truly individualized index on which to optimize antimicrobial therapy.

Furthermore, in place of an easily available individualized PK/PD index to guide the assessment of response to therapy, clinicians rely on clinical judgement, physiological parameters, and biochemical markers such as C-reactive protein (CRP) and procalcitonin (PCT) to assess individual patient response.^{78,79} In particular, CRP, an acute phase protein that is a non-specific marker of inflammation, is one of the most commonly used biomarkers during infection management in clinical practice.^{80–82} Despite its wide use in infection management, very little attempt has been made to link it directly to exposure–response using PK/PD modelling.

To address this, recent studies have reported the use of the ratio of the AUC to the EC₅₀ in paediatric populations.^{47,48} The EC₅₀ is the concentration of a drug (mg/L) that is estimated to induce a half-maximal antibacterial effect (such as reduction in serum CRP or galactomannan, a specific plasma marker in *Aspergillus* infection) for an individual patient. The AUC:EC₅₀ ratio can provide an *in vivo* estimate of drug response by linking drug exposure with

PD.^{47,48} Acting as an *in vivo* measure of potency, AUC:EC₅₀ enables an estimate of the host immune response to the invading organism. This has the potential to circumvent the problems associated with *in vitro* MIC estimation and may provide data that can drive the development of real-time algorithms for the delivery and control of individualized antimicrobial therapy. With the clinical validation of tools such as the AUC:EC₅₀ for predicting antimicrobial PD in individuals using markers such as CRP, future work must now explore the role of using newer infection-related biomarkers, such as procalcitonin and CD64 for improving the accuracy of these tools. Furthermore, exploration of similar methods for predicting toxicity (e.g. renal toxicity) may further enhance the individualization of therapy by including host, antimicrobial agent, and pathogen factors in estimations of the outcome of therapy.

Drug delivery

Whilst intravenous and oral delivery of agents, via infusion pump and personalized dosing alerts respectively, may be the initial routes for antimicrobial delivery using such control systems there is also the potential for delivery via microneedle systems in the future. Such microneedles are now under investigation for drug and vaccine delivery that provide dual functions of sensing and also drug delivery.⁵² However, in the field of infection, the rate of drug delivery that can be achieved may be hindered by certain drug characteristics (such as hydrophilic versus hydrophobic agents) and the volume of agent required to be delivered. However, this technology may pose an interesting avenue for certain challenging cohorts, such as paediatric patients, as well as for local antimicrobial therapy delivery, such as skin and soft tissue infections or penetration of collections.

Conclusions

Novel systems are urgently required to individualize delivery of antimicrobial therapy, to address the wide variations in PK currently observed across a range of patient populations, and minimize the impact of sub-optimal dosing on clinical outcomes and AMR. Closed-loop control utilizing dermal antimicrobial sensing techniques offers a potential new avenue of applied research that addresses many of the current barriers associated with drug monitoring and dose optimization tools. Furthermore, the nature of minimally invasive sensor technology provides a platform that can be used across a range of settings from the community to those in intensive care. To achieve this there must be cross-disciplinary collaboration to explore the utility of such technologies to optimize the precision of antimicrobial therapy by addressing a number of the hurdles that remain to implementing this type of technology.

Acknowledgements

We thank the National Institute of Health Research Imperial Biomedical Research Centre and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London in partnership with Public Health England and the NIHR Imperial Patient Safety Translational Research Centre.

Funding

This report is independent research funded by the National Institute for Health Research Invention for Innovation Grant (i4i), Enhanced, Personalized and Integrated Care for Infection Management at Point of Care (EPIC IMPOC), II-LA-0214-20008. A. C. G. is an NIHR Research Professor. This report was also supported by grants from (i) the Engineering, Medicine, Natural Sciences and Physical Sciences Bridging Research in Antimicrobial resistance: Collaboration and Exchange (EMBRACE), Imperial College Antimicrobial Research Collaborative; and (ii) Imperial College Biomedical Research Centre (BRC). J. A. R. wishes to recognize funding from the Australian National Health and Medical Research Council for Centre of Research Excellence (APP1099452) and a Practitioner Fellowship (APP1117065).

Transparency declarations

None to declare.

Author contributions

All authors contributed significantly to the literature review and writing of the manuscript. T. M. R. wrote the initial draft of the manuscript with all authors significantly contributing to the development and finalization of the version for submission.

Disclaimer

The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the UK Department of Health.

References

- 1 O'Neill J. 2016. *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations*. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.
- 2 Holmes AH, Moore LSP, Sundsfjord A *et al*. Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 2016; **387**: 176–87.
- 3 Roberts JA, Abdul-Aziz MH, Lipman J *et al*. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infect Dis* 2014; **14**: 498–509.
- 4 Perez F, El Chakhtoura NG, Papp-Wallace K *et al*. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply 'precision medicine' to antimicrobial chemotherapy? *Expert Opin Pharmacother* 2016; **17**: 761–81.
- 5 Abdul-Aziz MH, Roberts JA, Lipman J *et al*. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. *Semin Respir Crit Care Med* 2015; **36**: 136–53.
- 6 Cotta MO, Roberts JA, Lipman J. We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how? *Crit Care* 2016; **20**: 163.
- 7 Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. *Ann Intensive Care* 2011; **1**: 47.
- 8 Charmillon A, Novy E, Agrinier N *et al*. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β -lactam administration and therapeutic drug monitoring among critically ill patients in France. *Clin Microbiol Infect* 2016; **22**: 625–31.

- 9 Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β -lactams. *Crit Care* 2011; **15**: R206.
- 10 Huttner A, Harbarth S, Hope WW *et al.* Therapeutic drug monitoring of the β -lactam antibiotics: what is the evidence and which patients should we be using it for? *J Antimicrob Chemother* 2015; **70**: 3178–83.
- 11 Patel BM, Paratz J, See NC *et al.* Therapeutic drug monitoring of β -lactam antibiotics in burns patients—a one-year prospective study. *Ther Drug Monit* 2012; **34**: 160–4.
- 12 Roberts JA, Norris R, Paterson DL *et al.* Therapeutic drug monitoring of antimicrobials. *Br J Clin Pharmacol* 2012; **73**: 27–36.
- 13 Roberts JA, Paul SK, Akova M *et al.* DALI: Defining antibiotic levels in intensive care unit patients: Are current β -lactam antibiotic doses sufficient for critically ill patients? *Clin Infect Dis* 2014; **58**: 1072–83.
- 14 Felton TW, Roberts JA, Lodise TP *et al.* Individualization of piperacillin dosing for critically ill patients: Dosing software to optimize antimicrobial therapy. *Antimicrob Agents Chemother* 2014; **58**: 4094–102.
- 15 Carlier M, Stove V, Wallis SC *et al.* Assays for therapeutic drug monitoring of β -lactam antibiotics: a structured review. *Int J Antimicrob Agents* 2015; **46**: 367–75.
- 16 Souza MJ, Kulmann RR, Silva LM *et al.* Development and in-house validation of a microbiological assay for determination of cefepime in injectable preparations. *JAOAC Int* 2006; **89**: 1367–72.
- 17 Pickering MK, Brown SD. Assays for determination of ertapenem for applications in therapeutic drug monitoring, pharmacokinetics and sample stability. *Biomed Chromatogr* 2014; **28**: 1525–31.
- 18 Miranda Bastos AC, Vandecasteele SJ, Tulkens PM *et al.* Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. *J Pharm Biomed Anal* 2014; **90**: 192–7.
- 19 Zalewski P, Cielecka-Piontek J, Paczkowska M. Development and validation of stability-indicating HPLC method for simultaneous determination of meropenem and potassium clavulanate. *Acta Pol Pharm* 2014; **71**: 255–60.
- 20 Wolff F, Deprez G, Seyler L *et al.* Rapid quantification of six β -lactams to optimize dosage regimens in severely septic patients. *Talanta* 2013; **103**: 153–60.
- 21 Rawson TM, Moore LS, Hernandez B *et al.* A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately? *Clin Microbiol Infect* 2017; **23**: 524–32.
- 22 Wilhelm AJ, den Burger JCG, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. *Clin Pharmacokinet* 2014; **53**: 961–73.
- 23 Chong H. Paper-based microfluidic point-of-care diagnostic devices for monitoring drug metabolism. *J Nanomed Biotherapeut Discov* 2013; **3**: 1–2.
- 24 Kang JS, Lee MH. Overview of therapeutic drug monitoring. *Korean J Intern Med* 2009; **24**: 1–10.
- 25 Parker SL, Dorofaeff T, Lipman J *et al.* Is there a role for microsampling in antibiotic pharmacokinetic studies? *Expert Opin Drug Metab Toxicol* 2016; **5255**: 601–14.
- 26 Rawson TM, Sharma S, Georgiou P *et al.* *Towards a Minimally Invasive Device for β -lactam Monitoring in Humans*. 2017. http://ac.els-cdn.com/S1388248117301856/1-s2.0-S1388248117301856-main.pdf?_tid=8511cda4-7048-11e7-976d-00000aabb0f02&acdnat=1500884423_b35db9176145fbd9ccc62d4a0c7c1c04.
- 27 Reddy M, Herrero P, Sharkawy ME *et al.* Metabolic control with the bio-inspired artificial pancreas in adults with type 1 diabetes: a 24-hour randomized controlled crossover study. *J Diabetes Sci Technol* 2016; **10**: 405–13.
- 28 Sharma S, Huang Z, Rogers M *et al.* Evaluation of a minimally invasive glucose biosensor for continuous tissue monitoring. *Anal Bioanal Chem* 2016; **408**: 8427–35.
- 29 Yan G, Warner KS, Zhang J *et al.* Evaluation needle length and density of microneedle arrays in the pretreatment of skin for transdermal drug delivery. *Int J Pharm* 2010; **391**: 7–12.
- 30 Bariya SH, Gohel MC, Mehta TA *et al.* Microneedles: an emerging transdermal drug delivery system. *J Pharm Pharmacol* 2012; **64**: 11–29.
- 31 Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? *J Diabetes Sci Technol* 2016; **10**: 714–23.
- 32 Absalom AR, Sutcliffe N, Kenny GN. Closed-loop control of anesthesia using bispectral index. *Anesthesiology* 2002; **96**: 67–73.
- 33 Madhavan JS, Puri GD, Mathew PJ. Closed-loop isoflurane administration with bispectral index in open heart surgery: randomized controlled trial with manual control. *Acta Anaesthesiol Taiwan* 2011; **49**: 130–5.
- 34 El-Laboudi A, Oliver NS, Cass A *et al.* Use of microneedle array devices for continuous glucose monitoring: a review. *Diabetes Technol Ther* 2013; **15**: 101–15.
- 35 Trzebinski J, Sharma S, Radomska-Botelho Moniz A *et al.* Microfluidic device to investigate factors affecting performance in biosensors designed for transdermal applications. *Lab Chip* 2012; **12**: 348.
- 36 Roberts JA, Udy AA, Jarrett P *et al.* Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. *J Antimicrob Chemother* 2014; **70**: 1495–502.
- 37 Johnson BL, Damer KM, Walroth TA *et al.* A systematic review of vancomycin dosing and monitoring in burn patients. *J Burn Care Res* 2015; **36**: 641–50.
- 38 Roberts JA, Roberts MS, Robertson TA *et al.* Piperacillin penetration into tissue of critically ill patients with sepsis—bolus versus continuous administration? *Crit Care Med* 2009; **37**: 926–33.
- 39 Vincent J-L, Bassetti M, François B *et al.* Advances in antibiotic therapy in the critically ill. *Crit Care* 2016; **20**: 133.
- 40 Joukhadar C, Frossard M, Mayer BX *et al.* Impaired target site penetration of β -lactams may account for therapeutic failure in patients with septic shock. *Crit Care Med* 2001; **29**: 385–91.
- 41 Johnson MA, Moradi MH, eds. *PID Control*. London: Springer, 2005. <http://link.springer.com/10.1007/1-84628-148-2>.
- 42 Ahn H-S, Chen Y, Moore KL. *Iterative Learning Control*. London: Springer London, 2007. <http://link.springer.com/10.1007/978-1-84628-859-3>.
- 43 Wang Y, Gao F, Doyle FJ. Survey on iterative learning control, repetitive control, and run-to-run control. *J Process Control* 2009; **19**: 1589–600.
- 44 Madady A. PID type iterative learning control with optimal gains. *Int J Control Autom Syst* 2008; **6**: 194–203.
- 45 Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. *Pharmacol Rev* 2013; **65**: 1053–90.
- 46 Frimodt-Møller N. How predictive is PK/PD for antibacterial agents? *Int J Antimicrob Agents* 2002; **19**: 333–9.
- 47 Huurneman LJ, Neely M, Veringa A *et al.* Pharmacodynamics of voriconazole in children: Further steps along the path to true individualized therapy. *Antimicrob Agents Chemother* 2016; **60**: 2336–42.
- 48 Ramos-Martin V, Neely MN, McGowan P *et al.* Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. *J Antimicrob Chemother* 2016; **71**: 3168–78.
- 49 Henry S, McAllister DV, Allen MG *et al.* Microfabricated microneedles: a novel approach to transdermal drug delivery. *J Pharm Sci* 1998; **87**: 922–5.
- 50 Sharma S, Saeed A, Johnson C *et al.* Rapid, low cost prototyping of transdermal devices for personal healthcare monitoring. *Sens Biosensing Res* 2017; **13**: 104–8.
- 51 Moniz ARB, Michelakis K, Trzebinski J *et al.* Minimally invasive enzyme microprobes: an alternative approach for continuous glucose monitoring. *J Diabetes Sci Technol* 2012; **6**: 479–80.

- 52 Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. *Adv Drug Deliv Rev* 2012; **64**: 1547–68.
- 53 Ranamukhaarachchi SA, Padeste C, Dübner M *et al.* Integrated hollow microneedle-optofluidic biosensor for therapeutic drug monitoring in sub-nanoliter volumes. *Sci Rep* 2016; **6**: 29075.
- 54 Ferguson BS, Hoggarth DA, Maliniak D *et al.* Real-time, aptamer-based tracking of circulating therapeutic agents in living animals. *Sci Transl Med* 2013; **5**: 213ra165.
- 55 Lee H, Song C, Hong YS *et al.* Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module. *Sci Adv* 2017; **3**: e1601314.
- 56 Hayat A, Marty JL. Aptamer based electrochemical sensors for emerging environmental pollutants. *Front Chem* 2014; **2**: 41.
- 57 Gorchkov DV, Soldatkin AP, Maupas H *et al.* Correlation between the electrical charge properties of polymeric membranes and the characteristics of ion field effect transistors or penicillinase based enzymatic field effect transistors. *Anal Chim Acta* 1996; **331**: 217–23.
- 58 Healey BG, Walt DR. Improved fiber-optic chemical sensor for penicillin. *Anal Chem* 1995; **67**: 4471–6.
- 59 Lee SR, Rahman MM, Sawada K *et al.* Fabrication of a highly sensitive penicillin sensor based on charge transfer techniques. *Biosens Bioelectron* 2009; **24**: 1877–82.
- 60 O'Hare D. Biosensors and sensor systems. In: G Yang, ed. *Body Sensor Networks*. Springer, 2014. <http://link.springer.com/10.1007/978-1-4471-6374-9>.
- 61 Trouillon R, Combs Z, Patel BA *et al.* Comparative study of the effect of various electrode membranes on biofouling and electrochemical measurements. *Electrochem Commun* 2009; **11**: 1409–13.
- 62 Herrero P, Georgiou P, Oliver N *et al.* A bio-inspired glucose controller based on pancreatic β -cell physiology. *J Diabetes Sci Technol* 2012; **6**: 606–16.
- 63 Philip A, Rawson TM, Moore LSP *et al.* Closed-loop controller systems for the precision delivery of vancomycin: an in silico proof-of-concept. In: *Federation of Infection Society Annual Conference*, 2016. Abstract 5121. [http://www.journalofhospitalinfection.com/article/S0195-6701\(16\)30516-3/pdf](http://www.journalofhospitalinfection.com/article/S0195-6701(16)30516-3/pdf).
- 64 Ulldemolins M, Vaquer S, Llauradó-Serra M *et al.* β -Lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. *Crit Care* 2014; **18**: 227.
- 65 Cataldo MA, Tacconelli E, Grilli E *et al.* Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. *J Antimicrob Chemother* 2012; **67**: 17–24.
- 66 Wysocki M, Delatour F, Faurisson F *et al.* Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. *Antimicrob Agents Chemother* 2001; **45**: 2460–7.
- 67 Ulldemolins M, Martin-Loeches I, Llaurado-Serra M *et al.* Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. *J Antimicrob Chemother* 2016; **71**: 1651–9.
- 68 Roberts JA, Lipman J, Blot S *et al.* Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? *Curr Opin Crit Care* 2008; **14**: 390–6.
- 69 Roos JF, Lipman J, Kirkpatrick CMJ. Population pharmacokinetics and pharmacodynamics of ceftipime in critically ill patients against Gram-negative bacteria. *Intensive Care Med* 2007; **33**: 781–8.
- 70 Ramos-Martín V, Johnson A, Livermore J *et al.* Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. *J Antimicrob Chemother* 2016; 992–1002.
- 71 Udy AA, Lipman J, Jarrett P *et al.* Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? *Crit Care* 2015; **19**: 28.
- 72 Chagnac A, Weinstein T, Korzets A *et al.* Glomerular hemodynamics in severe obesity. *Am J Physiol Renal Physiol* 2000; **278**: F817–22.
- 73 Shimamoto Y, Fukuda T, Tanaka K *et al.* Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. *Intensive Care Med* 2013; **39**: 1247–52.
- 74 Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents. *Adv Drug Deliv Rev* 2014; **77**: 3–11.
- 75 Herrero P, Pesl P, Reddy M *et al.* Advanced insulin bolus advisor based on run-to-run control and case-based reasoning. *IEEE J Biomed Heal Informatics* 2015; **19**: 1087–96.
- 76 Phua J, Ngerng W, See K *et al.* Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. *Crit Care* 2013; **17**: R202.
- 77 Zarb P, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe. *Drugs* 2011; **71**: 745–55.
- 78 Rawson TM, Charani E, Moore LSP *et al.* Mapping the decision pathways of acute infection management in secondary care among UK medical physicians: a qualitative study. *BMC Med* 2016; **14**: 208.
- 79 de Jong E, van Oers JA, Beishuizen A *et al.* Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis* 2016; **16**: 819–27.
- 80 Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. *Open Forum Infect Dis* 2015; **2**: ofv098.
- 81 Kobeissi ZA, Zanotti-Cavazzoni SL. Biomarkers of sepsis. *Yearb Crit Care Med* 2010; **2010**: 227–8.
- 82 Nargis W, Ahamed B, Ibrahim M. Procalcitonin versus C-reactive protein: usefulness as biomarker of sepsis in ICU patient. *Int J Crit Illn Inj Sci* 2014; **4**: 195.
- 83 Nagaraj VJ, Jacobs M, Vattipalli KM *et al.* Nanochannel-based electrochemical sensor for the detection of pharmaceutical contaminants in water. *Environ Sci Process Impacts* 2013; **16**: 135–40.
- 84 Zhang K, Lu L, Wen Y *et al.* Facile synthesis of the necklace-like graphene oxide-multi-walled carbon nanotube nanohybrid and its application in electrochemical sensing of Azithromycin. *Anal Chim Acta* 2013; **787**: 50–6.
- 85 Pinacho DG, Sánchez-Baeza F, Pividori MI *et al.* Electrochemical detection of fluoroquinolone antibiotics in milk using a magneto immunosensor. *Sensors (Basel)* 2014; **14**: 15965–80.
- 86 Gayen P, Chaplin BP. Selective electrochemical detection of ciprofloxacin with a porous nafion/multiwalled carbon nanotube composite film electrode. *ACS Appl Mater Interfaces* 2016; **8**: 1615–26.
- 87 Theanponkrang S, Suginta W, Weingart H *et al.* Robotic voltammetry with carbon nanotube-based sensors: a superb blend for convenient high-quality antimicrobial trace analysis. *Int J Nanomedicine* 2015; **10**: 859–68.
- 88 Zhang F, Gu S, Ding Y *et al.* A novel sensor based on electropolymerization of β -cyclodextrin and l-arginine on carbon paste electrode for determination of fluoroquinolones. *Anal Chim Acta* 2013; **770**: 53–61.
- 89 Giroud F, Gorgy K, Gondran C *et al.* Impedimetric immunosensor based on a polypyrrole-antibiotic model film for the label-free picomolar detection of ciprofloxacin. *Anal Chem* 2009; **81**: 8405–9.
- 90 Moraes FC, Silva TA, Cesarino I *et al.* Antibiotic detection in urine using electrochemical sensors based on vertically aligned carbon nanotubes. *Electroanalysis* 2013; **25**: 2092–9.
- 91 Zhang X, Zhang Y-C, Zhang J-W. A highly selective electrochemical sensor for chloramphenicol based on three-dimensional reduced graphene oxide architectures. *Talanta* 2016; **161**: 567–73.
- 92 Jakubec P, Urbanová V, Medříková Z *et al.* Advanced sensing of antibiotics with magnetic gold nanocomposite: electrochemical detection of chloramphenicol. *Chemistry* 2016; **22**: 14279–84.

- 93** Govindasamy M, Chen SM, Mani V *et al.* Molybdenum disulfide nano-sheets coated multiwalled carbon nanotubes composite for highly sensitive determination of chloramphenicol in food samples milk, honey and powdered milk. *J Colloid Interface Sci* 2017; **485**: 129–36.
- 94** Karthik R, Govindasamy M, Chen SM *et al.* Green synthesized gold nanoparticles decorated graphene oxide for sensitive determination of chloramphenicol in milk, powdered milk, honey and eye drops. *J Colloid Interface Sci* 2016; **475**: 46–56.
- 95** Meenakshi S, Pandian K, Jayakumari LS *et al.* Enhanced amperometric detection of metronidazole in drug formulations and urine samples based on chitosan protected tetrasulfonated copper phthalocyanine thin-film modified glassy carbon electrode. *Mater Sci Eng C Mater Biol Appl* 2016; **59**: 136–44.
- 96** Gan T, Shi Z, Sun J, Liu Y. Simple and novel electrochemical sensor for the determination of tetracycline based on iron/zinc cations-exchanged montmorillonite catalyst. *Talanta* 2014; **121**: 187–93.
- 97** Liu S, Wang Y, Xu W *et al.* A novel sandwich-type electrochemical apta-sensor based on GR-3D Au and aptamer-AuNPs-HRP for sensitive detection of oxytetracycline. *Biosens Bioelectron* 2017; **88**: 181–7.
- 98** Rastgar S, Shahrokhan S. Nickel hydroxide nanoparticles-reduced graphene oxide nanosheets film: Layer-by-layer electrochemical preparation, characterization and rifampicin sensory application. *Talanta* 2014; **119**: 156–63.
- 99** Janata J, City SL. pH-based enzyme potentiometric sensors. *Anal Chem* 1985; **57**: 1924–5.
- 100** Anzai J, Hashimoto J, Osa T *et al.* Penicillin sensors based on an ion-sensitive coated with stearic acid Langmuir-Blodgett field effect membrane transistor. *Anal Sci* 1988; **4**: 247–50.
- 101** Yerian TD, Christian GD, Ruzicka J. Flow injection analysis as a diagnostic technique for development and testing of chemical sensors. *Anal Chim Acta* 1988; **204**: 7–28.
- 102** Gao X, Zhen R, Zhang Y, Grimes CA. Detecting penicillin in milk with a wireless magnetoelastic biosensor. *Sen Lett* 2009; **7**: 6–10.
- 103** Wang H, Wang Y, Liu S *et al.* Signal-on electrochemical detection of antibiotics at zeptomole level based on target-aptamer binding triggered multiple recycling amplification. *Biosens Bioelectron* 2016; **80**: 471–6.
- 104** Daprà J, Lauridsen LH, Nielsen AT *et al.* Comparative study on aptamers as recognition elements for antibiotics in a label-free all-polymer biosensor. *Biosens Bioelectron* 2013; **43**: 315–20.
- 105** Pikkemaat MG. Microbial screening methods for detection of antibiotic residues in slaughter animals. *Anal Bioanal Chem* 2009; **395**: 893–905.
- 106** Huet AC, Delahaut P, Fodey T *et al.* Advances in biosensor-based analysis for antimicrobial residues in foods. *Trends Anal Chem* 2010; **29**: 1281–94.
- 107** Willander M, Khun K, Ibupoto ZH. Metal oxide nanosensors using polymeric membranes, enzymes and antibody receptors as ion and molecular recognition elements. *Sensors (Switzerland)* 2014; **14**: 8605–32.
- 108** Ismail F, Adeloju SB. Galvanostatic entrapment of penicillinase into polypyrrolamine films and its utilization for the potentiometric determination of penicillin. *Sensors* 2010; **10**: 2851–68.
- 109** Bi X, Hartono D, Yang KL. Real-time liquid crystal pH sensor for monitoring enzymatic activities of penicillinase. *Adv Funct Mater* 2009; **19**: 3760–5.
- 110** Gonçalves LM, Callera WFA, Sotomayor MDPT *et al.* Penicillinase-based amperometric biosensor for penicillin G. *Electrochem Commun* 2014; **38**: 131–3.
- 111** Müntze GM, Baur B, Schäfer W *et al.* Quantitative analysis of immobilized penicillinase using enzyme-modified AlGaIn/GaN field-effect transistors. *Biosens Bioelectron* 2015; **64**: 605–10.
- 112** Siqueira JR, Abouzar MH, Poghossian A *et al.* Penicillin biosensor based on a capacitive field-effect structure functionalized with a dendrimer/carbon nanotube multilayer. *Biosens Bioelectron* 2009; **25**: 497–501.
- 113** Cháfer-Pericás C, Maquieira Á, Puchades R. Fast screening methods to detect antibiotic residues in food samples. *Trends Anal Chem* 2010; **29**: 1038–49.
- 114** Rowe AA, Miller EA, Plaxco KW. Reagentless measurement of aminoglycoside antibiotics in blood serum via an electrochemical, ribonucleic acid aptamer-based biosensor. *Anal Chem* 2010; **82**: 7090–5.
- 115** Wu X, Kuang H, Hao C *et al.* Paper supported immunosensor for detection of antibiotics. *Biosens Bioelectron* 2012; **33**: 309–12.
- 116** Schoukroun-Barnes LR, Wagan S, White RJ. Enhancing the analytical performance of electrochemical RNA aptamer-based sensors for sensitive detection of aminoglycoside antibiotics. *Anal Chem* 2014; **86**: 1131–7.
- 117** Han S, Li B, Song Z *et al.* A kanamycin sensor based on an electrosynthesized molecularly imprinted poly-o-phenylenediamine film on a single-walled carbon nanohorn modified glassy carbon electrode. *Analyst* 2016; **142**: 218–23.
- 118** Nikolaus N, Strehlitz B. DNA-aptamers binding aminoglycoside antibiotics. *Sensors (Basel)* 2014; **14**: 3737–55.
- 119** Chiu M-H, Yang H-H, Liu C-H *et al.* Determination of lincomycin in urine and some foodstuffs by flow injection analysis coupled with liquid chromatography and electrochemical detection with a preanodized screen-printed carbon electrode. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; **877**: 991–4.
- 120** Zacco E, Adrian J, Galve R *et al.* Electrochemical magneto immunosensing of antibiotic residues in milk. *Biosens Bioelectron* 2007; **22**: 2184–91.
- 121** Joseph R, Girish Kumar K. Differential pulse voltammetric determination and catalytic oxidation of sulfamethoxazole using [5,10,15,20-tetrakis (3-methoxy-4-hydroxy phenyl) porphyrinato] Cu (II) modified carbon paste sensor. *Drug Test Anal* 2010; **2**: 278–83.
- 122** Sgobbi LF, Razzino CA, Machado SAS. A disposable electrochemical sensor for simultaneous detection of sulfamethoxazole and trimethoprim antibiotics in urine based on multiwalled nanotubes decorated with Prussian blue nanocubes modified screen-printed electrode. *Electrochim Acta* 2016; **191**: 1010–7.